履歴書

谷﨑　潤子

たにざき　じゅんこ

近畿大学医学部　内科学教室腫瘍内科部門
講師
Department of Medical Oncology,
Kindai University, Faculty of Medicine
〒590-0197 大阪府堺市南区三原台 1 丁 14 番 1 号

学歴

2007年3月卒　近畿大学医学部
2009 年 4 月～2012 年 3 月　近畿大学大学院医学研究科腫瘍病態制御学(早期卒業)
2012 年 3 月　博士（医学）取得（近畿大学）

勤務歴

2007 年 4 月～2009 年 3 月　近畿大学医学部附属病院　臨床研修医
2009 年 4 月～2012 年 7 月　近畿大学医学部附属病院　腫瘍内科 助教
2012年8月～2015年3月　Dana－Farber Cancer Institute　Post-doctoral Fellow
2015 年 4 月～2018 年 3 月　近畿大学医学部内科学腫瘍内科部門　助教
2018 年 4 月～2021 年 3 月　市立岸和田市民病院　腫瘍内科　医長
2021 年 4 月～現在に至る　近畿大学医学部内科学腫瘍内科部門　講師

専門分野

腫瘍内科学、腫瘍生物学、固形癌全般（特に肺癌、頭頸部癌、原発不明癌）

所属学会等

日本内科学会、日本臨床腫瘍学会、日本肺癌学会、日本癌学会
ASCO、ESMO、IASLC

認定医等の資格

日本内科学会　認定内科医、総合内科専門医
日本臨床腫瘍学会　がん薬物療法専門医、指導医

委員会等

日本肺癌学会　ガイドライン検討委員会　薬物療法及び集学的治療小委員会　委員（2018 年 12 月～2022 年 12 月）
日本臨床腫瘍学会　がん免疫療法ガイドライン　改訂第 3 版ワーキンググループ委員
日本臨床腫瘍学会　保険委員会（2022 年 3 月～2024 年 3 月）
日本臨床腫瘍学会　国際委員会　委員（2026 年 4 月～現在に至る）
日本肺癌学会　国際委員会　委員（2018 年 12 月~2020 年 12 月、2022 年 12 月～現在）、教育研修委員会　委員（2022 年 12 月～現在に至る）、肺がん医療向上委員会（2024 年 11 月～現在に至る）、IASLC 連携小委員会（2025 年 1 月～現在に至る）
IASLC Rare tumor committee (SCLC subgroup) （2023 年 12 月～現在に至る）
IASLC DEI taskforce （2022 年 12 月～現在に至る）

賞罰

平成 19 年度 近畿大学学長賞
平成 23 年度近畿大学校友会長賞
令和 4 年（2022）　西日本がん研究機構（WJOG）　有吉福岡賞
令和 5 年（2023）日本臨床腫瘍学会　奨励賞
令和 7 年（2025）日本臨床腫瘍学会 Annals of oncology 賞

助成金

#　2010 年（平成 22 年度）財団法人大阪難病研究財団　難病および精神疾患に関する医学研究助成金「EML4-ALK 陽性肺癌における ALK 阻害剤への耐性機序の検討」
#　2011 年　上原記念生命科学財団　(平成 23 年度)ポストドクトラルフェローシップ「癌シグナル経路と分子標的薬の効果の検討」
#　2022 年～2024 年　科学研究費助成事業　基盤研究（C）研究代表者「免疫チェックポイント阻害薬による免疫関連有害事象の発症及び重症化のリスク因子解析」

論文

Kanemura H, **Tanizaki J**, Matsumoto K, Masuishi T, Isobe T, Kenmotsu H, Sunakawa Y, Shimizu T, Chiba Y, Yamamoto N, Nakagawa K, Hayashi H.
Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).
Eur J Cancer. 2026;238:116684.

Soo RA, Fernandez-Penas P, Li M, Voon PJ, **Tanizaki J**, Tseng JS, Tan C, Dong XR, Prabhash K, Kim HR, Hasegawa K, Parkinson N, Kam J, Simoes J, McGeachie M, Lu S, Pavlakis N.
Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer.
Lung Cancer. 2026;216:109405.

Lu S, Pulla MP, Mascarenhas E, **Tanizaki J**, Kim HR, Liu Y, Feng S, Zhang B, Toms L, Yang JC, Goldberg SB.
TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with EGFR-mutated locally advanced or metastatic NSCLC.
Ther Adv Med Oncol. 2026;18:17588359261430561.

Konya Y, **Tanizaki J**, Onishi K, Matsuzoe H, Kanemura H, Takahama T, Tanaka K, Nakazawa G, Hayashi H.
Recovery from fulminant immune-related myocarditis induced by ipilimumab plus nivolumab in malignant pleural mesothelioma: a case report.
BMC Pulm Med. 2026 Mar 10;26(1):182. doi: 10.1186/s12890-026-04193-3.
PMID: 41808091

Watanabe R, Mitani S, Okura M, Inagaki C, **Tanizaki J**, Tanaka K, Iwasa T, Yonesaka K, Hayashi H.
Development of Second Primary Malignancies in Long-term Survivors of Unresectable Esophageal Cancer.
Cancer Diagn Progn. 2026 Mar-Apr;6(2):359-367. doi: 10.21873/cdp.10534.
PMID: 41778251

Kurosaki T, Kanemura H, Otani T, Kawanaka Y, Fukuda Y, Kudo K, **Tanizaki J**, Suzuki S, Tomida S, Sakai K, Chiba Y, Ito A, Nishio K, Nakagawa K, Hayashi H.
Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer.
Lung Cancer. 2025 Sep;207:108723. doi: 10.1016/j.lungcan.2025.108723.

PMID: 40865373

Kawanaka Y, Yonesaka K, **Tanizaki J**, Maenishi O, Sakai K, Kakimi K, Nishio K, Hayashi H.
Case Report: A small cell lung cancer transformed from an EGFR-mutated adenocarcinoma demonstrated a long-term remission to anti PD-1 antibody.
Front Oncol. 2025;15:1651248.

Hakozaki T, Tanaka K, Shiraishi Y, Sekino Y, Mitome N, Okuma Y, Aiba T, Utsumi T, **Tanizaki J**, Azuma K, Hara S, Morita R, Niho S, Yokoyama T, Toyozawa R, Horinouchi H, Okamoto I, Hosomi Y, Ohe Y.
Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON).
J Thorac Oncol. 2025 Jul;20(7):912-927. doi: 10.1016/j.jtho.2025.02.026.
PMID: 40058642

Zenke Y, Niho S, Toi Y, Yamaguchi M, Hara S, Akazawa Y, Hosomi Y, Yonesaka K, Akamatsu H, Yokoyama T, **Tanizaki J**, Ueno K, Gyotoku H, Misumi T, Nakagawa K, Yamamoto N, Tsuboi M.
Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study.
Lung Cancer. 2025 Aug;206:108633. doi: 10.1016/j.lungcan.2025.108633.
PMID: 40602204

Shukuya T, Asao T, Goto Y, Mimori T, Takayama K, Kaira K, Tanaka H, Ko R, Amano Y, Tachihara M, Suzuki T, **Tanizaki J**, Sugawara S, Zenke Y, Shirai Y, Hayashi T, Mori K, Takahashi K.
Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial.
Lancet Oncol. 2025 Mar;26(3):331-342. doi: 10.1016/S1470-2045(25)00001-4.
PMID: 40049197

Yonesaka K, Kurosaki T, **Tanizaki J**, Kawakami H, Tanaka K, Maenishi O, Takamura S, Sakai K, Chiba Y, Teramura T, Goto H, Otsuka E, Okida H, Funabashi M, Hashimoto Y, Hirotani K, Kamai Y, Kagari T, Nishio K, Kakimi K, Hayashi H.
Chromosomal Instability Is Associated with cGAS-STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer.
Cells. 2025;14(6):447.

Tan DS, Nadal E, Cheema P, Wu YL, Ahn MJ, **Tanizaki J**, Grainger E, Nizialek E, Forcina A, van der Gronde T, Yu HA.
TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with EGFR-mutated advanced NSCLC.
Ther Adv Med Oncol. 2025;17:17588359251385410. doi: 10.1177/17588359251385410.
PMID: 41466843

Ohta R, Tanaka K, Miyata M, **Tanizaki J**, Hayashi H.
Peritoneal Metastasis Mimicking Chemotherapy-Induced Complications in Lung Adenocarcinoma: A Diagnostic Challenge of a Case Report.
Cureus. 2025 Apr;17(4):e82530. doi: 10.7759/cureus.82530.
PMID: 40385873

Ohta R, Tanaka K, Miyata M, **Tanizaki J**, Hayashi H.
Diagnostic and Therapeutic Challenges in an Older Patient With Concurrent Small-Cell Lung Carcinoma and Primary Duodenal Adenocarcinoma: A Case Report.
Cureus. 2025 Apr;17(4):e83040. doi: 10.7759/cureus.83040.
PMID: 40421353

Mochizuki S, Ohta R, Konya Y, Isomoto K, Takahama T, **Tanizaki J**, Hayashi H.
Paraneoplastic Syndromes Mimicking Dermatomyositis and RS3PE Syndrome in Cancer of Unknown Primary Origin: A Case Report.
Cureus. 2025 Mar;17(3):e81376. doi: 10.7759/cureus.81376.
PMID: 40291331

Lim SM, Shim JSG, Shim HS, **Tanizaki J**, Nutzinger J, Cho BC, Soo RA.
What Is On the Horizon for the Diagnosis and Treatment of SCLC and Large Cell Neuroendocrine Cancer?
JTO Clin Res Rep. 2025;6(9):100871.

Shiraishi N, Takahama T, Sakai K, Tanaka K, Nakagawa Y, Kanemura H, Nakayama T, Kawanaka Y, Kurosaki T, Suzuki S, Iwasa T, **Tanizaki J**, Inagaki C, Yonesaka K, Fukuoka K, Mitsudomi T, Nishio K, Hayashi H, Nakagawa K.
Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing.
Thorac Cancer. 2025;16(3):e70007.

Fujita Y, Matsuoka H, Chiba Y, Tsurutani J, Yoshida T, Sakai K, Nakura M, Sakamoto R, Makimura C, Ohtake Y, Tanaka K, Hayashi H, Takahama T, **Tanizaki J**, Koyama A, Nishio K, Nakagawa K.
Dual single-nucleotide polymorphism biomarker combination for opioid selection to treat cancer pain.
Mol Clin Oncol. 2025 Feb;22(2):14. doi: 10.3892/mco.2024.2809.
PMID: 39720462

Top 20 *EGFR*+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating *EGFR* Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.
Ou SI, Le X, Nagasaka M, Reungwetwattana T, Ahn MJ, Lim DWT, Santos ES, Shum E, Lau SCM, Lee JB, Calles A, Wu F, Lopes G, Sriuranpong V, **Tanizaki J**, Horinouchi H, Garassino MC, Popat S, Besse B, Rosell R, Soo RA.Lung Cancer (Auckl). 2024 Jun 22;15:87-114. doi: 10.2147/LCTT.S463429. eCollection 2024.PMID: 38938224

#
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.
Haratani K, Nakamura A, Mamesaya N, Sawa K, Shiraishi Y, Saito R, **Tanizaki J**, Tamura Y, Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Tokito T, Nagata K, Masuda T, Nakamura Y, Sakai K, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H.Br J Cancer. 2024 May;130(11):1783-1794. doi: 10.1038/s41416-024-02662-2. Epub 2024 Mar 22.PMID: 38519705

#
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Imai H, Kijima T, Azuma K, Kishi K, Saito H, Yamaguchi T, **Tanizaki J**, Yoneshima Y, Fujita K, Watanabe S, Kitazono S, Fukuhara T, Hataji O, Toi Y, Mizutani H, Hamakawa Y, Maemondo M, Ohsugi T, Suzuki K, Horinouchi H, Ohe Y.
Jpn J Clin Oncol. 2024 Apr 6;54(4):452-462. doi: 10.1093/jjco/hyad195.
PMID: 38271158

Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, Goto M, Chiba Y, Tomida S, Ota T, Haratani K, Takahama T, **Tanizaki J**, Yoshida T, Iwasa T, Tanaka K, Takeda M, Hirano T, Yoshida H, Ozasa H, Sakamori Y, Sakai K, Higuchi K, Uga H, Suminaka C, Hirai T, Nishio K, Nakagawa K, Honjo T.
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.

J Clin Invest. 2024 Apr 1;134(7):e168318. doi: 10.1172/JCI168318.
PMID: 38557498

Hagiwara S, **Tanizaki J**, Hayashi H, Komeda Y, Nishida N, Yoshida A, Yamamoto T, Matsubara T, Kudo M.
Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy.
Cancer Rep (Hoboken). 2024 Jan 9;7(2):e1960. doi: 10.1002/cnr2.1960. Online ahead of print.
PMID: 38196303

Tanizaki J, Hayashi H.
Unraveling Pseudo Kidney Injury: The Significance of Understanding Our "MATE" in Molecular-Targeted Therapies.
J Thorac Oncol. 2024 Jan;19(1):15-17. doi: 10.1016/j.jtho.2023.11.001.
PMID: 38185510 No abstract available.

Tanizaki J, Kuroda H, Yokoyama T, Takahama M, Shoda H, Nakamura A, Kitamura Y, Mamesaya N, Kadota Y, Sawa K, Okishio K, Okada M, Suminaka C, Noda K, Sakai K, Chiba Y, Nishio K, Chamoto K, Honjo T, Yamamoto N, Nakagawa K, Hayashi H.
Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy.
JTO Clin Res Rep. 2023 Oct 13;4(12):100590. doi: 10.1016/j.jtocrr.2023.100590. eCollection 2023 Dec.
PMID: 38029041 Free PMC article.

Masuda T, Miura S, Sato Y, Tachihara M, Bessho A, Nakamura A, Miyawaki T, Yoshimine K, Mori M, Shiraishi H, Hamai K, Haratani K, Maeda S, Tabata E, Kitagawa C, **Tanizaki J**, Imai T, Nogami S, Yamamoto N, Nakagawa K, Hattori N.
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer.
Sci Rep. 2023 Nov 13;13(1):19729. doi: 10.1038/s41598-023-45337-3.
PMID: 37957228 Free PMC article.

Asao T, Shukuya T, Mimori T, Goto Y, Tanaka H, Takayama K, Tsubata Y, Tachihara M, Suzuki T, Kaira K, Ko R, Zenke Y, Akamatsu H, **Tanizaki J**, Ikeda S, Sugawara S, Mizutani H, Mori K, Takahashi K.

Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101).
Clin Lung Cancer. 2023 Nov;24(7):e247-e253. doi: 10.1016/j.cllc.2023.05.004. Epub 2023 May 19.
PMID: 37316381 Clinical Trial.

Haratani K, Nakamura A, Mamesaya N, Mitsuoka S, Yoneshima Y, Saito R, **Tanizaki** J, Fujisaka Y, Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Sato Y, Nakano Y, Otani T, Sakai K, Tomida S, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H.
Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE).
J Thorac Oncol. 2023 Oct;18(10):1334-1350. doi: 10.1016/j.jtho.2023.06.012. Epub 2023 Jun 25.
PMID: 37364849

Fujita Y, Matsuoka H, Chiba Y, Tsurutani J, Yoshida T, Sakai K, Nakura M, Sakamoto R, Makimura C, Ohtake Y, Tanaka K, Hayashi H, Takeda M, Okuno T, Takegawa N, Haratani K, Takahama T, **Tanizaki J**, Koyama A, Nishio K, Nakagawa K.
Novel single nucleotide polymorphism biomarkers to predict opioid effects for cancer pain.
Oncol Lett. 2023 Jul 4;26(2):355. doi: 10.3892/ol.2023.13941. eCollection 2023 Aug.
PMID: 37545623

Tanizaki J, Nakagawa K, Hayashi H.
Reply to the Letter to the Editor 'Does the result of a small-scale phase II study of nivolumab for cancer of unknown primary justify regulatory approval?' by Y. Sasaki; E. Sato & C. Sakaguchi.
Ann Oncol. 2022 Oct;33(10):1083-1084. doi: 10.1016/j.annonc.2022.06.006. Epub 2022 Jun 27.
PMID: 35772666

Kanemura H, Hayashi H, Tomida S, **Tanizaki J**, Suzuki S, Kawanaka Y, Tsuya A, Fukuda Y, Kaneda H, Kudo K, Takahama T, Imai R, Haratani K, Chiba Y, Otani T, Ito A, Sakai K, Nishio K, Nakagawa K.
The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC.
JTO Clin Res Rep. 2022 Jul 1;3(8):100373. doi: 10.1016/j.jtocrr.2022.100373. eCollection 2022 Aug.

PMID: 35941997

Hayashi H, Sugawara S, Fukuda Y, Fujimoto D, Miura S, Ota K, Ozawa Y, Hara S, **Tanizaki J**, Azuma K, Omori S, Tachihara M, Nishino K, Bessho A, Chiba Y, Haratani K, Sakai K, Nishio K, Yamamoto N, Nakagawa K.
A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).
Clin Cancer Res. 2022 Mar 1;28(5):893-902. doi: 10.1158/1078-0432.CCR-21-3194.
PMID: 34921023

Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y, Miura Y, Segawa Y, Takahashi S, Iwamoto Y, Kidera Y, Fukuoka K, Ito A, Chiba Y, Sakai K, Nishio K, Nakagawa K, Hayashi H.
Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary.
Ann Oncol. 2022 Feb;33(2):216-226. doi: 10.1016/j.annonc.2021.11.009. Epub 2021 Nov 26.
PMID: 34843940

Suzuki S, Yonesaka K, Teramura T, Takehara T, Kato R, Sakai H, Haratani K, **Tanizaki J**, Kawakami H, Hayashi H, Sakai K, Nishio K, Nakagawa K.
Correction: KRAS Inhibitor Resistance in MET-Amplified KRAS G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.
Clin Cancer Res. 2022 Jan 15;28(2):428. doi: 10.1158/1078-0432.CCR-21-4240.
PMID: 35045961

Suzuki S, Haratani K, Hayashi H, Chiba Y, **Tanizaki J**, Kato R, Mitani S, Kawanaka Y, Kurosaki T, Hasegawa Y, Okabe T, Tanaka K, Akashi Y, Ozaki T, Nishio K, Ito A, Nakagawa K.
Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer.
Eur J Cancer. 2022 Jan;161:44-54. doi: 10.1016/j.ejca.2021.11.011. Epub 2021 Dec 15.
PMID: 34922263

Sakata S, Otsubo K, Yoshida H, Ito K, Nakamura A, Teraoka S, Matsumoto N, Shiraishi Y, Haratani K, Tamiya M, Ikeda S, Miura S, **Tanizaki J,** Omori S, Yoshioka H, Hata A, Yamamoto N, Nakagawa K.
Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.
Cancer Sci. 2022 Jan;113(1):221-228. doi: 10.1111/cas.15176. Epub 2021 Nov 7.

PMID: 34704312

The safety and efficacy of durvalumab consolidation therapy in the management of patients with stage III non-small-cell lung cancer and preexisting interstitial lung disease.
Kawanaka Y, Yasuda Y, **Tanizaki J**, Iwashima D, Nonagase Y, Uemasu K, Hirayama Y, Ogura M, Ozaki T, Takahashi KI.
Respir Investig. 2022 Sep;60(5):667-673. doi: 10.1016/j.resinv.2022.05.004. Epub 2022 Jun 18.PMID: 35725721

Yonesaka K, **Tanizaki J**, Maenishi O, Haratani K, Kawakami H, Tanaka K, Hayashi H, Sakai K, Chiba Y, Tsuya A, Goto H, Otsuka E, Okida H, Kobayashi M, Yoshimoto R, Funabashi M, Hashimoto Y, Hirotani K, Kagari T, Nishio K, Nakagawa K.
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
Clin Cancer Res. 2022 Jan 15;28(2):390-403. doi: 10.1158/1078-0432.CCR-21-3359. Epub 2021 Dec 17.
PMID: 34921025

Suzuki S, Yonesaka K, Teramura T, Takehara T, Kato R, Sakai H, Haratani K, **Tanizaki J**, Kawakami H, Hayashi H, Sakai K, Nishio K, Nakagawa K.
KRAS inhibitor-resistance in MET-amplified KRAS G12C non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms.
Clin Cancer Res. 2021 Oct 15;27(20):5697-5707.

Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Haratani K, Itoh S, Uemura T, Morinaga R, Takahama T, Nakashima K, Tachihara M, Saito G, **Tanizaki J**, Otsubo K, Ikeda S, Matsumoto H, Hara S, Hata A, Masuda T, Yamamoto N.
A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC.
JTO Clin Res Rep. 2022;3(2):100265.

Kato R, Hayashi H, Sakai K, Suzuki S, Haratani K, Takahama T, **Tanizaki J**, Nonagase Y, Tanaka K, Yoshida T, Takeda M, Yonesaka K, Kaneda H, Nishio K, Nakagawa K.
CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinib.
Int J Clin Oncol. 2021 Sep;26(9):1628-1639. doi: 10.1007/s10147-021-01947-3. Epub 2021 Jun 11.
PMID: 34117553

Nishiyama O, Shimizu S, Haratani K, Isomoto K, **Tanizaki J**, Hayashi H, Yamazaki R, Oomori T, Nishikawa Y, Sano A, Nakagawa K, Tohda Y.
Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
BMC Pulm Med. 2021 May 8;21(1):155. doi: 10.1186/s12890-021-01523-5.
PMID: 33964920

Ninomiya K, Teraoka S, Zenke Y, Kenmotsu H, Nakamura Y, Okuma Y, Tamiya A, Nosaki K, Morise M, Aokage K, Oya Y, Kozuki T, Sakamoto T, Tanaka K, Tanaka H, **Tanizaki J**, Miura S, Mizutani H, Miyauchi E, Yamaguchi O, Ebi N, Goto Y, Sasaki T, Daga H, Morita S, Yamanaka T, Amano S, Hasegawa K, Imamura CK, Suzuki K, Nakajima K, Nishimoto H, Oizumi S, Hida T, Hotta K, Takiguchi Y.
Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations.
JTO Clin Res Rep. 2020 Oct 12;2(1):100107. doi: 10.1016/j.jtocrr.2020.100107. eCollection 2021 Jan.
PMID: 34589972

Hayashi H, Niwa T, Yokoyama T, **Tanizaki J**, Ozaki T, Yoshioka H, Kurata T, Tamura Y, Fujisaka Y, Tanaka K, Hasegawa Y, Kudo K, Chiba Y, Nakagawa K.
Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer.
Oncologist . 2021 Jan;26(1):19-e52. doi: 10.1002/ONCO.13524. Epub 2020 Sep 28
PMID: 32918791

Kobayashi M, Masuda K, Noda Y, **Tanizaki J**, Yamabe E, Tanaka A, Koumura N, Kozasa K, Naoi H, Otsuka H, Yokoi T.
A case of sarcomatoid malignant peritoneal mesothelioma diagnosed by laparoscopy.
Gynecol Oncol Rep. 2020 Sep 11;34:100642. doi: 10.1016/j.gore.2020.100642. eCollection 2020 Nov.
PMID: 33015277

Isomoto K, Haratani K, Hayashi H, Shimizu S, Shuta T, Niwa T, Yokoyama T, Fukuda Y, Chiba Y, Kato R, **Tanizaki J**, Tanaka K, Takeda M, Ogura T, Ishida T, Ito A, Nakagawa K.
Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer.
Clin Cancer Res. 2020 Apr 15;26(8):2037-2046. doi: 10.1158/1078-0432.CCR-19-2027. Epub 2020 Jan 14.PMID: 31937613

Yonesaka K, Iwama E, Hayashi H, Suzuki S, Kato R, Watanabe S, Takahama T, **Tanizaki** J, Tanaka K, Takeda M, Sakai K, Azuma K, Chiba Y, Atagi S, Nishio K, Okamoto I, Nakagawa K.

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Sci Rep. 2019 Dec 20;9(1):19501.

Haratani K, Hayashi H, Takahama T, Nakamura Y, Tomida S, Yoshida T, Chiba Y, Sawada T, Sakai K, Fujita Y, Togashi Y, **Tanizaki J**, Kawakami H, Ito A, Nishio K, Nakagawa K.
Clinical and immune profiling for cancer of unknown primary site.
J Immunother Cancer. 2019 Sep 13;7(1):251.

Watanabe S, Yonesaka K, **Tanizaki J**, Nonagase Y, Takegawa N, Haratani K, Kawakami H, Hayashi H, Takeda M, Tsurutani J, Nakagawa K.
Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Cancer Med. 2019 Mar;8(3):1258-1268.

Watanabe S, Hayashi H, Haratani K, Shimizu S, **Tanizaki J**, Sakai K, Kawakami H, Yonesaka K, Tsurutani J, Togashi Y, Nishio K, Ito A, Nakagawa K.
Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
Cancer Sci. 2019 Jan;110(1):52-60.

Jang J, Son J, Park E, Kosaka T, Saxon JA, De Clercq DJH, Choi HG, **Tanizaki J**, Eck MJ, Jänne PA, Gray NS.
Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor.
Angew Chem Int Ed Engl. 2018 Sep 3;57(36):11629-11633.

Tanizaki J, Chiba Y, Haratani K, Hayashi H, Nakagawa K.
In Reply.
J Thorac Oncol. 2018 May;13(5):e86-e87.

Makuuchi Y, Hayashi H, Haratani K, **Tanizaki J**, Tanaka K, Takeda M, Sakai K, Shimizu S, Ito A, Nishio K, Nakagawa K.
A case of ALK-rearranged non-small cell lung cancer that responded to ceritinib after development of resistance to alectinib.
Oncotarget. 2018 May 1;9(33):23315-23319.

Takeda M, Sakai K, Hayashi H, Tanaka K, **Tanizaki J**, Takahama T, Haratani K, Nishio K, Nakagawa K.
Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2.
Oncotarget. 2018 Apr 20;9(30):21132-21140.

Junko Tanizaki, Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba, Yasushi Nakamura, Kimio Yonesaka, Keita Kudo, Hiroyasu Kaneda, Yoshikazu Hasegawa, Kaoru Tanaka, Masayuki Takeda, Akihiko Ito, and Kazuhiko Nakagawa
Peripheral blood biomarkers associated with clinical outcome in non–small cell lung cancer patients treated with nivolumab
J Thorac Oncol. 2018 Jan;13(1):97-105. doi: 10.1016/j.jtho.2017.10.030. Epub 2017 Nov 21.

Watanabe S, Yoshida T, Kawakami H, Takegawa N, **Tanizaki J**, Hayashi H, Takeda M, Yonesaka K, Tsurutani J, Nakagawa K.
T790M-selective EGFR-TKI combined with dasatinib as an optimal strategy for overcoming EGFR-TKI resistance in T790M-positive non-small cell lung cancer.
Mol Cancer Ther. 2017 Aug 24. pii: molcanther.0351.2017. doi: 10.1158/1535-7163.MCT-17-0351. [Epub ahead of print]

Kato R, Hayashi H, **Tanizaki J**, Tanaka K, Takeda M, Nakagawa K.
Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab.
ESMO Open. 2017 Mar 28;2(1):e000145.

Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, **Tanizaki J**, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K.
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Ann Oncol. 2017 Jul 1;28(7):1532-1539.

Kosaka T, **Tanizaki J**, Paranal RM, Endoh H, Lydon C, Capelletti M, Repellin CE, Choi J, Ogino A, Calles A, Ercan D, Redig AJ, Bahcall M, Oxnard GR, Eck MJ, Jänne PA.
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
Cancer Res. 2017 May 15;77(10):2712-2721.

Kawakami H, **Tanizaki J**, Tanaka K, Haratani K, Hayashi H, Takeda M, Kamata K, Takenaka M, Kimura M, Chikugo T, Sato T, Kudo M, Ito A, Nakagawa K.
Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer.
Invest New Drugs. 2017 Aug;35(4):529-536.

Tanizaki J, Hayashi H, Kimura M, Tanaka K, Takeda M, Shimizu S, Ito A, Nakagawa K.
Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression.
Lung Cancer. 2016 Dec;102:44-48.

Tanizaki J, Banno E, Togashi Y, Hayashi H, Sakai K, Takeda M, Kaneda H, Nishio K, Nakagawa K.
Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
Lung Cancer. 2016 Nov;101:11-15

Nonagase Y, Yonesaka K, Kawakami H, Watanabe S, Haratani K, Takahama T, Takegawa N, Ueda H, **Tanizaki J**, Hayashi H, Yoshida T, Takeda M, Chiba Y, Tamura T, Nakagawa K, Tsurutani J.
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Oncotarget. 2016 Dec 20;7(51):84860-84871.

Hibi M, Kaneda H, **Tanizaki J**, Sakai K, Togashi Y, Terashima M, De Velasco MA, Fujita Y, Banno E, Nakamura Y, Takeda M, Ito A, Mitsudomi T, Nakagawa K, Okamoto I, Nishio K.
FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
Cancer Sci. 2016 Nov;107(11):1667-1676.

Watanabe S, Takeda M, Takahama T, Iwasa T, Tsurutani J, **Tanizaki J.** Shimizu T, Sakai K, Wada Y, Isogai N, Nishio K, Nakagawa K.
Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease.
Invest New Drugs. 2016 Jun;34(3):394-6.

Tanizaki J, Ercan D, Capelletti M, Dodge M, Xu C, Bahcall M, Tricker EM, Butaney M, Calles A, Sholl LM, Hammerman PS, Oxnard GR, Wong KK, Jänne PA.
Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.
Cancer Res. 2015 Aug 1;75(15):3139-46. doi: 10.1158/0008-5472.CAN-14-3771. Epub 2015 Jun 5.

Tan L*, Wang J*, **Tanizaki J***, Huang Z*, Aref AR, Rusan M, Zhu SJ, Zhang Y, Ercan D, Liao RG, Capelletti M, Zhou W, Hur W, Kim N, Sim T, Gaudet S, Barbie DA, Yeh JR, Yun CH, Hammerman PS, Mohammadi M, Jänne PA, Gray NS.
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):E4869-77
*** equally contributed authors**

Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, **Tanizaki J,** Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I.

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer. Clin Cancer Res. 2015 May 27 . pii: clincanres.0016.2015.

Tsurutani J, Kuroi K, Iwasa T, Miyazaki M, Nishina S, Makimura C, **Tanizaki J**, Okamoto K, Yamashita T, Aruga T, Shigekawa T, Komoike Y, Saeki T, Nakagawa K.
Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer.
Cancer Sci. 2015 Jun;106(6):734-9. doi: 10.1111/cas.12658. Epub 2015 Apr 9

Kawakami H, Okamoto I, Okamoto W, **Tanizaki J**, Nakagawa K, Nishio K.
Targeting MET Amplification as a New Oncogenic Driver.
Cancers (Basel). 2014 Jul 22;6(3):1540-52.

Hayashi H, Okamoto I, **Tanizaki J**, Tanaka K, Okuda T, Kato A, Nishimura Y, Nakagawa K.
Cystic brain metastasis in non-small-cell lung cancer with ALK rearrangement.
J Clin Oncol. 2014 Dec 20;32(36):e122-4.

Matsuoka H, Tsurutani J, **Tanizaki J**, Iwasa T, Komoike Y, Koyama A, Nakagawa K.
Regression of brain metastases from breast cancer with eribulin: a case report.
BMC Res Notes. 2013;6:541.

Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, Kaneda H, Takezawa K, Kuwata K, Yamaguchi H, Hatashita E, Nishio K, Nakagawa K.
Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
Clin Cancer Res. 2012 Nov 15;18(22):6219-26

Kaneda H, Okamoto I, Sakai K, **Tanizaki J**, Takeda M, Nishio K, Nakagawa K.
Marked response to both S-1 and pemetrexed in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinoma.
Acta Oncol. 2012 Sep;51(7):942-4.

Tanizaki J, Okamoto I, Takezawa K, Sakai K, Azuma K, Kuwata K, Yamaguchi H, Hatashita E, Nishio K, Janne PA, Nakagawa K.
Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells.
Br J Cancer. 2012 Feb 14;106(4):763-7.

Tanizaki J, Okamoto I, Sakai K, Nakagawa K.
Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification.
Br J Cancer. 2011 Sep 6;105(6):807-13.

Tanizaki J, Okamoto I, Okamoto K, Takezawa K, Kuwata K, Yamaguchi H, Nakagawa K.
MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
J Thorac Oncol. 2011 Oct;6(10):1624-31

Tanizaki J, Okamoto I, Fumita S, Okamoto W, Nishio K, Nakagawa K.
Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Oncogene. 2011 Sep 29;30(39):4097-106.

Takezawa K, Okamoto I, **Tanizaki J**, Kuwata K, Yamaguchi H, Fukuoka M, Nishio K, Nakagawa K.
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Mol Cancer Ther. 2010 Jun;9(6):1647-56

Tanizaki J, Okamoto I, Takezawa K, Tsukioka S, Uchida J, Kiniwa M, Fukuoka M, Nakagawa K.
Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
Mol Cancer Ther. 2010 May;9(5):1198-207.

語学検定

IELTS CEFR Level C1 (Listening 8.5, Reading 8.5, Writing 7.0, Speaking 7.5, Overall Band Score 8.0)　2016/12/17

招待講演・シンポジウム・教育講演（主要なもの）

国際学会（演者）

2026 年　IASLC 2026 World Conference on Lung Cancer (WCLC 2026), Seoul
Educational Session ES24.02: Next-Generation T-cell Engagers and Beyond – Translating Novel Biologics into Clinical Practice
Clinical Exchange Session: State of the Art in ES-SCLC: Current First-Line Standards and Evolving Practice

2026 年　European Lung Cancer Congress 2026 (ELCC 2026), Copenhagen
Educational Session: Beyond monoclonal antibodies: Targeting strategies with bispecific and trispecific antibodies

2025 年　IASLC 2025 World Conference on Lung Cancer (WCLC 2025), Barcelona
Workshop – Panel Discussion: Expert Insights on Publishing and Presentations

2024 年　European Lung Cancer Congress 2024 (ELCC 2024), Prague
Educational Session: Small cells – Still a big issue

2024 年　IASLC 2024 Asia Conference on Lung Cancer (ACLC 2024), Hong Kong
Educational Session ES07.02: Systemic Therapy and the Role of Immunotherapy in Thymoma

2022 年　IASLC 2022 Asia Conference on Lung Cancer (ACLC 2022), Nara
Education Session 02-03: How We Select Patients for Chemo-Immuno Surgery vs. Chemo-Immuno-Radiation

2022 年　IASLC 2022 World Conference on Lung Cancer (WCLC 2022), Vienna
Education Session: Biomarker Analysis of the Tumor Microenvironment and Tumor-Immune Cell Interactions Using High-Plex Spatial and Single-Cell Studies

国際学会（座長）

2025 年　IASLC 2025 World Conference on Lung Cancer (WCLC 2025), Barcelona
SCLC: The Knowns and Unknowns in Everyday Practice with Expert Insights

2025 年　European Lung Cancer Congress 2025 (ELCC 2025), Paris
Multidisciplinary Tumour Board: How to manage locally advanced NSCLC with poor lung function

2023 年　ESMO Asia Congress 2023, Singapore
Mini Oral Session 2: Thoracic cancer

2023 年　IASLC 2023 World Conference on Lung Cancer (WCLC 2023), Singapore
ES07: Challenging Therapeutic Targets in Lung Cancer
MA15: Bringing New Discoveries into Early Phase Clinical Trials

国内学会（演者）

2025 年　第 66 回日本肺癌学会学術集会（東京）
ワークショップ「非小細胞肺癌における HER2 標的治療開発の最前線」

2025 年　第 22 回日本臨床腫瘍学会学術集会（神戸）
教育講演「原発不明癌―診断・治療の実践的なアプローチ方法―」
シンポジウム 11「EGFR exon20 ins 遺伝子変異陽性肺癌に対する治療戦略」

2024 年　第 65 回日本肺癌学会学術集会（横浜）
教育講演「最新の肺癌免疫療法 2024」

2024 年　第 21 回日本臨床腫瘍学会学術集会（名古屋）
教育講演「原発不明癌に対する治療戦略」

シンポジウム 23「Perioperative treatment for non-small cell lung cancer with driver gene alterations」

2023 年　第 20 回日本臨床腫瘍学会学術集会（福岡）
教育講演「原発不明癌に対する治療戦略」

2022 年　第 19 回日本臨床腫瘍学会学術集会（京都）
Presidential Symposium 6「Therapeutic strategy of immune checkpoint inhibitors for CUP」

2019 年　第 60 回日本肺癌学会学術集会（大阪）
シンポジウム「EGFR 遺伝子変異陽性肺癌における血管新生阻害剤併用療法」

Selected presentation

2020ASCO virtual scientific program, Special Clinical Science Symposium, Abst 106#

NivoCUP: An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary.
Junko Tanizaki, Kan Yonemori, Kohei Akiyoshi, Hironobu Minami, Hiroki Ueda, Yuichi Takiguchi, Chihiro Nakayama Kondoh, Yoshihiko Segawa, Shin Takahashi, Yasuo Iwamoto, Yasuhiro Kidera, Kazuya Fukuoka, Yasushi Nakamura, Yasutaka Chiba, Kazuto Nishio, Kazuhiko Nakagawa, Hidetoshi Hayashi
DOI: 10.1200/JCO.2020.38.15_suppl.106
Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 106-106.

2017, IASLC and 18th World Conference on Lung Cancer　2017
Junko Tanizaki, K Haratani, Hidetoshi Hayashi, Y Chiba, Kimio Yonesaka, K Kudo,H Kaneda, Y Hasegawa, K Tanaka, M Takeda, Kazuhiko Nakagawa
Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.

2010, 101st AACR Annual Meeting,
Junko Tanizaki, Isamu Okamoto, Ken Takezawa, Sayaka Tsukioka, Junji Uchida, Mamoru Kiniwa, Masahiro Fukuoka, Kazuhiko Nakagawa.
Synergistic antitumor effects of combination therapy with S-1 and HER2 targeting agents in gastric cancer with HER2 amplification.